Status:

COMPLETED

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

Lead Sponsor:

Bionomics Limited

Conditions:

Social Anxiety Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distre...

Detailed Description

This is a randomized, double-blind, placebo-controlled, 3-arm, parallel-group, multi-center study. Participants will attend a Screening Visit to confirm eligibility and then return to the clinic withi...

Eligibility Criteria

Inclusion

  • Participant has a current diagnosis of Social Anxiety Disorder (SAD) as defined in DSM-5 and confirmed by Structured Clinical Interview for DSM-5 Disorders - Clinical Trials version (SCID-5-CT).
  • Liebowitz Social Anxiety Scale (LSAS) total score of ≥70
  • Suitable contraception use in line with protocol requirements
  • Ability to swallow tablets

Exclusion

  • History of schizophrenia, bipolar disorder, or psychotic disorders, or has a current clinically predominant diagnosis of any other Axis I disorder, other than SAD
  • Hamilton Rating Scale for Depression (HAM-D) score of ≥18
  • Moderate or severe alcohol-use disorder, or any other substance-use disorder (any severity) in the past 12 months
  • Use of psychotropic medications within 30 days of screening. Daily use of benzodiazepines within 90 days of screening.
  • Previous participation in a study that involved a speaking challenge.
  • Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk

Key Trial Info

Start Date :

February 2 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 17 2022

Estimated Enrollment :

151 Patients enrolled

Trial Details

Trial ID

NCT05193409

Start Date

February 2 2022

End Date

October 17 2022

Last Update

March 18 2025

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

PREVAIL Study Clinical Trial Site

Beverly Hills, California, United States, 90210

2

PREVAIL Study Clinical Trial Site

Encino, California, United States, 91316

3

PREVAIL Study Clinical Trial Site

Glendale, California, United States, 91204

4

PREVAIL Study Clinical Trial Site

New Haven, Connecticut, United States, 33122